ALDENSTROM'S macroglobulinemia (WM) ac- counts for approximately 2% of hematologic cancers and affects approximately 1,500 Americans each year. The disease is more frequent among older persons and there may be a genetic predisposition, as suggested by family clusters."' The original description of WM focused on bone marrow infiltration by plasmacytoid lymphocytes and a high level of circulating macroglobulin (IgM).3 Many aspects of the biology and clinical features of this disease were summarized r e ~e n t l y . ~, ~ This review focuses on recent advances in the pathogenesis of complications caused by the elevated IgM and on the treatment of macroglobulinemic lymphoma.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (1994) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: